Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.84 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.75 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losartan SCHEMBL4222 | 0.99 | AGTR1 (0.86) | AGTR1AGTR2GP6 | |
| SCHEMBL20257387 | 0.93 | AGTR1 (0.81) | AGTR1AGTR2GP6 | |
| Losartan SCHEMBL14169312 | 0.92 | AGTR1 (0.80) | AGTR1AGTR2GP6 | |
| Losartan SCHEMBL2577425 | 0.92 | AGTR1 (0.74) | AGTR1AGTR2GP6 | |
| Losartan SCHEMBL31663637 | 0.91 | AGTR1 (0.73) | AGTR1AGTR2GP6 | |
| SCHEMBL3633085 | 0.91 | AGTR1 (0.78) | AGTR1AGTR2GP6 | |
| SCHEMBL8468357 | 0.89 | AGTR1 (0.76) | AGTR1AGTR2GP6 | |
| SCHEMBL20257373 | 0.89 | AGTR1 (0.76) | AGTR1AGTR2GP6 | |
| SCHEMBL2615537 | 0.88 | AGTR1 (0.69) | AGTR1AGTR2GP6 | |
| SCHEMBL2834891 | 0.88 | GP6 (0.77) | AGTR1AGTR2GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527879-B1 | SYNERGISTIC THERAPEUTIC COMPOSITIONS AND METHODS | PFIZER (US) | 1997-02-05 | — | — | EP | claimed |
| CN-101237892-A | Method for conjugating molecules containing an aminothiol to a carrier | AMGEN INC (US) | 2008-08-06 | — | — | CN | disclosed |
| EP-1544198-B1 | A process for the preparation of crystalline losartan potassium | DIPHARMA SPA (IT) | 2008-06-04 | — | — | EP | disclosed |
| EP-1544198-A1 | A process for the preparation of crystalline losartan potassium | Dipharma S.p.A. (IT) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131040-A1 | Process for the preparation of crystalline losartan potassium | DIPHARMA S.P.A. (IT) | 2005-06-16 | — | — | US | disclosed |
| EP-0527879-B1 | SYNERGISTIC THERAPEUTIC COMPOSITIONS AND METHODS | PFIZER (US) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131040-A1 | Process for the preparation of crystalline losartan potassium | REN, AGT, ACE | AGTR1 4/4885AGTR2 5/4885GP6 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.